MedTrace Logo

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

NCT04676334 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-05-07

Study results available
· View outcomes & findings →

Summary

This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit. Participants in long-term follow-up (LTFU) in a parent study may also enroll in this study for continued data collection, as applicable based on parent study objectives.

Conditions

Interventions

DRUG

Rucaparib

Rucaparib will be administered daily.

Sponsors & Collaborators

  • pharmaand GmbH

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2023-03-08
Completion
2023-03-08
FDA Drug
Yes

Countries

  • Canada
  • Israel
  • Italy
  • Poland
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676334 on ClinicalTrials.gov